ASSESSMENT OF EFFICACY OF TYROSINE KINASE INHIBITORS IN TREATMENT OF CHRONIC MYELOID LEUKEMIA

被引：0

作者：

Yadrikhinskaya, V. N. ^{[1
,2
]}

Mulina, I. I. ^{[3
,4
]}

Sannikova, A. N. ^{[5
]}

Palshina, A. M. ^{[1
,2
]}

Sleptsova, S. S. ^{[1
,6
,7
]}

Aleksandrova, T. N. ^{[8
]}

机构：

[1] MK Ammosov North Eastern Fed Univ, Med Sci, Inst Med, Ojunsky St 27, Yakutsk 677000, Russia

[2] Dept Hosp Therapy Occupat Dis & Clin Pharmacol, Ojunsky St 27, Yakutsk 677000, Russia

[3] Minist Healthcare Republ Sakha Yakutia, Sergelyakhskoe Shosse 4, Yakutsk 677019, Russia

[4] Dept Hematol Republican Hosp 1 Natl Ctr Med, Sergelyakhskoe Shosse 4, Yakutsk 677019, Russia

[5] Natl Ctr Med, Dept Hematol, Sergelyakhskoe Shosse 4, Yakutsk 677019, Russia

[6] MK Ammosov North Eastern Fed Univ, Minist Healthcare Republ Sakha Yakutia, Inst Med, Ojunsky St 27, Yakutsk 677000, Russia

[7] MK Ammosov North Eastern Fed Univ, Sci, Ojunsky St 27, Yakutsk 677000, Russia

[8] MK Ammosov North Eastern Fed Univ, Inst Med, Dept Internal Dis & Gen Med, Ojunsky St 27, Yakutsk 677000, Russia

来源：

YAKUT MEDICAL JOURNAL | 2016年 / 04期

关键词：

chronic myeloid leukemia; tyrosine kinase inhibitors; imatinib;

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

This research demonstrated treatment results of 45 patients with chronic myeloid leukemia who were monitored from 2006 to 2015 year. The article is aimed to evaluate a frequency of achievement of hematologic, cytogenetic, molecular responses in patients administered with tyrosine kinase inhibitors, prevalence of resistance to imatinib and its toxicity. It is shown that the treatment of choice for CML is tyrosine kinase inhibitor - imatinib. The use of tyrosine kinase inhibitors allows to reach deep cytogenetic and molecular remission in patients with chronic myeloid leukemia which leads to increased survival. Authors have noted a high prevalence of primary and secondary resistance to first generation tyrosine kinase inhibitor - imatinib. Investigation of results demonstrated that regular hematological, cytogenetic and molecular monitoring is required for effective disease control.

引用

页码：30 / 33

页数：4

共 7 条

[1]

Abdulkadurov KM, 2013, VESTNIK GEMATOLOGII, V9, P4

[2]

Davydkin I.L., 2013, EFFEKTIVNAYA FARMAKO, V46, P14

[3]

Kusnetsova E.Y., 2011, FUNDAMENTALNYE ISSLE, P95

[4] Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia [J].

O'Brien, SG ;

Guilhot, F ;

Larson, RA ;

Gathmann, I ;

Baccarani, M ;

Cervantes, F ;

Cornelissen, JJ ;

Fischer, T ;

Hochhaus, A ;

Hughes, T ;

Lechner, K ;

Nielsen, JL ;

Rousselot, P ;

Reiffers, J ;

Saglio, G ;

Shepherd, J ;

Simonsson, B ;

Gratwohl, A ;

Goldman, JM ;

Kantarjian, H ;

Taylor, K ;

Verhoef, G ;

Bolton, AE ;

Capdeville, R ;

Druker, BJ ;

Durrant, S ;

Schwarer, A ;

Joske, D ;

Seymour, J ;

Grigg, A ;

Ma, D ;

Arthur, C ;

Bradstock, K ;

Joshua, D ;

Louwagie, A ;

Martiat, P ;

Straetmans, N ;

Bosly, A ;

Shustik, C ;

Lipton, J ;

Forrest, D ;

Walker, I ;

Roy, DC ;

Rubinger, M ;

Bence-Bruckler, I ;

Kovacs, M ;

Turner, AR ;

Birgens, H ;

Bjerrum, O ;

Facon, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (11) :994-1004

[5]

Savelyeva M.I., 2012, KREMLEVSKAYA MEDITSI, P52

[6]

Shukhov O.A., 2015, THESIS, P113

[7]

Turkina A.G., 2015, EFFEKTIVNAYA FARMAKO, P8

← 1 →